Enrollment in the dose escalation part of the Phase I clinical trial has been completed. Enrollment is starting for the dose expansion part of the Phase I clinical trial in multiple sites in the United Kingdom and Asia. For more information, please contact MiNA at email@example.com.
MiNA Therapeutics is an associate company of Sosei. In May 2017, Sosei acquired a 25.6% equity share and an exclusive option to potentially acquire MiNA Therapeutics.